JNJ Price Suggests Caution as Company Nears 52-Week High

Johnson & Johnson is trading near its 52-week high of $274.90 at $261.81, and investors are wondering whether to buy or hold.

The company's strong fundamentals, including a clean pipeline, resilient guidance, and the pending DePuy Synthes orthopaedics spinoff, have driven the stock up 54.82% over the past year.

However, some analysts argue that the valuation is high, with a trailing P/E of 30, while quarterly earnings growth is -0.9% year over year.

The company's MedTech segment is also experiencing difficulties, with Abiomed declining 2% in Q2 due to physician caution after a neutral U.K. trial.